Biosimilar monoclonal antibodies are defined as biological molecules derived from the living cells or the organisms. They have the complex, large proteins of biosimilar family used over by immune system to identify and neutralize the foreign bodies associated to bacteria, viruses, and others. These antibodies are largely administered over by the treatment of diseases associated to rheumatoid arthritis, Hodgkins lymphoma, chronic lymphocytic leukemia, and others. The Biosimilar Monoclonal Antibody market to witness the prominent growth owing to incorporation of the advanced mAbs (Monoclonal Antibodies). Moreover, the demand & adoption of biosimilar monoclonal antibody will further increase by making the way over the growth of market.
According to study, “Global Biosimilar Monoclonal Antibody Market to reach
USD 32.05 Billion by 2026” the key companies operating in
the global biosimilar monoclonal antibody market are Allergan plc, BIOCAD
BioXpress, Therapeutics SA, Biocon Limited, Boehringer Ingelheim GmbH, Celltrion
Inc, Coherus BioSciences Inc, Dr. Reddys Laboratories Ltd, Genor BioPharma Co
Ltd., Intas Pharmaceuticals Limited.
The biosimilar monoclonal antibody market is
driven by growth in geriatric population, followed by increase in demand for
cost effective treatment among patients, and rise in prevalence of diseases,
such as rheumatoid arthritis and cancer. However, high cost associated with the
manufacturing process of these drugs and severe government regulations towards
the absence of pre-analytical tests may impact the market. Moreover, increase
in government focus on enhancing health care facilities and growth in
collaboration among the Local Players are key opportunities for market.
Based on geography, the North-American region
holds major share in global biosimilar monoclonal antibody market owing to
presence of advanced healthcare facilities, increase in product approvals,
favorable reimbursement scenario and rise in adoption of biosimilar monoclonal
antibodies in the region. Whereas, the Asian-Pacific and European regions are
projected to witness higher growth rate due to rise in public-private
initiative aimed towards boosting advance research practices coupled with
increase in investment to promote Biosimilar Monoclonal Antibody research over
the forecast period. In upcoming years, it is estimated that future of the
global market will be bright caused by increase in focus on research and
development (R&D) contributing to innovative product pipeline and growth in
health care infrastructure during the forecast period. The global biosimilar
monoclonal antibody market is valued approximately at US $27.84 Billion in 2018
and is expected to grow with a healthy growth rate of more than 35.70% over the
forecast period 2019 to 2026.
For
More Information refer to below link:-
Global
Biosimilar Monoclonal Antibody Market
Related
Report:-
Global
Biosimilar Monoclonal Antibody Market Report 2020 by Key Players, Types,
Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19
Worldwide Spread)
Contact Us:-
Ken ResearchAnkur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
No comments:
Post a Comment